Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
1.420
+0.068 (5.04%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Armata Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Deborah Birx |
Contact Details
Address: 5005 McConnell Avenue Los Angeles, California 90066 United States | |
| Phone | 310 665 2928 |
| Website | armatapharma.com |
Stock Details
| Ticker Symbol | ARMP |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921114 |
| CUSIP Number | 04216R102 |
| ISIN Number | US04216R1023 |
| Employer ID | 91-1549568 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Deborah L. Birx M.D. | Chief Executive Officer and Director |
| David D. House | Senior Vice President of Finance and Principal Financial Officer |
| Peter Hubbard | Vice President of Operations |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 10-K | Annual Report |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 12, 2025 | SCHEDULE 13D/A | Filing |
| Mar 12, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 13, 2024 | 10-Q | Quarterly Report |